Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-19-004404
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-21 17:01:11
Reporting Period:
2019-02-19
Accepted Time:
2019-02-21 17:01:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750019 Tcr2 Therapeutics Inc. TCRR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1575745 Morana Jovan-Embiricos C/o Tcr2 Therapeutics Inc.
100 Binney Street
Cambridge MA 02142
Yes No Yes No
1600769 Ltd Holdings Globeways 3Rd Floor, Geneve Place, Waterfront Dr
Po Box 3175, Road Town, Tortola, Bvi
Ch-1205 Geneva V8
No No Yes No
1767388 Ltd 2017 Ii Bioscience F2 C/o Lj Partnership, 8, Rue
Saint-Leger,
Geneva V8 CH-1205
No No Yes No
1767390 Ltd 2017 I Captial F2 C/o Lj Partnership, 8, Rue
Saint-Leger,
Geneva V8 CH-1205
No No Yes No
1767391 Ltd 2015 I Capital F2 C/o Lj Partnership, 8, Rue
Saint-Leger,
Geneva V8 CH-1205
No No Yes No
1767396 Ltd Mg F2 C/o Lj Partnership, 8, Rue
Saint-Leger,
Geneva V8 CH-1205
No No Yes No
1767397 F2 - Tpo Investments Llc C/o Lj Partnership, 8, Rue
Saint-Leger,
Geneva V8 CH-1205
No No Yes No
1767415 F2 Bbg Llc C/o Singer Mckeon Inc, 8 West 38Th St
Suite 1001
New York NY 10018
No No Yes No
1767418 F2 Capital I 2019, Llc C/o Singer Mckeon Inc, 8 West 38Th St
Suite 1001
New York NY 10018
No No Yes No
1768161 Ltd Ii Holdings Globeways 3Rd Floor, Geneve Place, Waterfront Dr
Po Box 3175, Road Town Tortola, Bvi
Ch-1205 Geneva V8
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-19 1,614,515 $0.00 1,614,515 No 4 C Indirect By Fund
Common Stock Acquisiton 2019-02-19 193,742 $0.00 193,742 No 4 C Indirect By Fund
Common Stock Acquisiton 2019-02-19 410,168 $0.00 410,168 No 4 C Indirect By Fund
Common Stock Acquisiton 2019-02-19 282,540 $0.00 282,540 No 4 C Indirect By Fund
Common Stock Acquisiton 2019-02-19 403,629 $0.00 403,629 No 4 C Indirect By Fund
Common Stock Acquisiton 2019-02-19 200,000 $15.00 200,000 No 4 P Indirect By Fund
Common Stock Acquisiton 2019-02-19 166,667 $15.00 166,667 No 4 P Indirect By Fund
Common Stock Acquisiton 2019-02-19 166,667 $15.00 449,207 No 4 P Indirect By Fund
Common Stock Acquisiton 2019-02-19 133,333 $15.00 536,962 No 4 P Indirect By Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Fund
No 4 C Indirect By Fund
No 4 C Indirect By Fund
No 4 C Indirect By Fund
No 4 C Indirect By Fund
No 4 P Indirect By Fund
No 4 P Indirect By Fund
No 4 P Indirect By Fund
No 4 P Indirect By Fund
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-02-19 10,000,001 $0.00 1,614,515 $0.00
Common Stock Series B Preferred Stock Disposition 2019-02-19 1,200,000 $0.00 193,742 $0.00
Common Stock Series B Preferred Stock Disposition 2019-02-19 2,540,500 $0.00 410,168 $0.00
Common Stock Series B Preferred Stock Disposition 2019-02-19 1,750,000 $0.00 282,540 $0.00
Common Stock Series B Preferred Stock Disposition 2019-02-19 2,500,000 $0.00 403,629 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
  2. The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  3. Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering..
  4. The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  5. The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  6. The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  7. The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  8. The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  9. The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.